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MEIOTIC RECOMBINATION, CROSS-REACTIVITY, AND PERSISTENCE IN
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Abstract. We incorporate a representation of Plasmodium falciparum recombination within a discrete-event model
of malaria transmission. We simulate the introduction of a new parasite genotype into a human population in which
another genotype has reached equilibrium prevalence and compare the emergence and persistence of the novel re-
combinant forms under differing cross-reactivity relationships between the genotypes. Cross-reactivity between the
parental (initial and introduced) genotypes reduces the frequency of appearance of recombinants within three years
of introduction from 100% to 14%, and delays their appearance by more than a year, on average. Cross-reactivity
between parental and recombinant genotypes reduces the frequency of appearance to 36% and increases the probability
of recombinant extinction following appearance from 0% to 83%. When a recombinant is cross-reactive with its
parental types, its probability of extinction is influenced by cross-reactivity between the parental types in the opposite
manner; that is, its probability of extinction after appearance decreases. Frequencies of P. falciparum outcrossing are
mediated by frequencies of mixed-genotype infections in the host population, which are in turn mediated by the
structure of cross-reactivity between parasite genotypes. The three leading hypotheses about how meiosis relates to
oocyst production lead to quantitative, but no qualitative, differences in these results.
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The life cycle of Plasmodium falciparum, the major cause
of malaria morbidity and mortality worldwide, involves ob-
ligate sexual recombination, which occurs within bloodmeals
taken by Anopheles mosquitoes from infectious humans. The
frequency with which these P. falciparum matings involve
outcrossing rather than selfing, and thus the degree to which
the species is characterized by panmixia rather than facul-
tative clonality, has been vigorously debated for a decade,
almost exclusively at the two extremes (Ayala et al. 1998;
Walliker et al. 1998). However, recent evidence suggests that
inferred P. falciparum population structures may differ be-
tween sites and times and seem to exhibit intermediate levels
of outcrossing (Paul et al. 1999; Anderson et al. 2000a). Not
surprisingly, these conflicting analyses are complicated by
their dependence on the specific loci examined, and in par-
ticular by the degree to which these markers may engage host
immunological responses.
Plasmodium infection of a vertebrate begins with a small
inoculum of sporozoites from the salivary glands of a blood-
feeding Anopheles mosquito. Sporozoites penetrate liver
cells, transform, and multiply to produce thousands of free
merozoites. Each of these asexual merozoites invades a red
blood cell, completes another phase of multiplication, then
bursts the cell, releasing eight to 32 more merozoites to in-
vade more red blood cells. This blood cycle may be repeated
many times, in the course of which some of the invading
merozoites instead develop into the sexual, nonreplicating
transmission stages known as gametocytes. If gametocytes
are taken up by a feeding Anopheles, gametes from male and
female gametocytes may unite to form zygotes, and, in turn,
the oocysts from which infective sporozoites arise. The zy-
gote is the sole diploid stage in the Plasmodium life cycle:
Meiosis occurs within a few hours of zygote formation, and
the remaining weeks or months of the life cycle consist of
haploid forms.
Thus, the basic biology of Plasmodium argues that fre-
quencies of parasite transmission between host and vector
constitute one set of bounds for recombination rates, and that
numbers and relative densities of infectious genotypes within
a host constitute one set of bounds for outcrossing events.
Although mechanisms for even these minimal constraints are
largely unknown, it seems certain that immunological re-
sponses are strongly influential, such that some parasite ge-
notypes might not co-occur in humans or transit to mosqui-
toes independently (Ferreira et al. 1998; Gilbert et al. 1998;
Healer et al. 1999; Snounou et al. 1999). It is particularly
important to understand the dynamics of interactions between
human immunity and parasite recombination because, by di-
rect selection or by altering human immune responses, in-
fectivity, or other factors, antimalarial vaccines or drugs may
alter patterns of parasite recombination so as to either hasten
or retard the decline of their own efficacies (Buckling et al.
1999; Baird 2000).
Discrete-event models of malaria transmission adapt the
population-compartment scheme of classic models to the lev-
el of individuals within interacting host and vector popula-
tions (Fig. 1). They embed simple, explicit models of P.
falciparum life-cycle dynamics within individual humans and
individual mosquitoes in thousands of interacting represen-
tations of individual humans and individual mosquitoes
(McKenzie et al. 1998, 1999). This approach intrinsically
encompasses multiple interactions among P. falciparum var-
iants, their partitioning across individual human character-
istics and infection histories, and their sampling through mos-
quito transmission.
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FIG. 1. A schematic of the discrete-event model, representing the status of a female Anopheles mosquito (top) and of a human (bottom)
with respect to appropriate stages of the Plasmodium falciparum life cycle. Vector bloodmeals allow parasite transmission, linking the
two phases. McKenzie et al. (1998) provides a detailed description.
The major conclusion from our basic model was that the
daily mortality of the vector and the duration of human in-
fectivity influence malaria prevalence in a human population
more strongly than does the duration of human immunity to
reinfection. Our results agreed with those of the classic dif-
ferential-equation models of malaria, where they were com-
parable, but we also demonstrated that ostensibly identical
representations of human immunity in differential-equation,
differential-delay-equation, and discrete-event models may
in fact be incommensurable. An expanded model encom-
passed the transmission of multiple parasite phenotypes—
phenotypes either fully independent or interactive through
complete cross-reactivity. With independent phenotypes,
mixed infections occurred in humans at the frequencies ex-
pected under standard statistical hypotheses of independence,
whereas with cross-reactivity, mixed infections occurred at
frequencies far below those expected; in either case, mixed
infections occurred in mosquitoes at frequencies above those
expected (in line with field data on mixed-species Plasmo-
dium infections; McKenzie and Bossert 1997a, 1999). This
juxtaposition suggested intriguing implications for outcross-
ing rates, in that with independent phenotypes, a mixed in-
fection in a human might derive from sequential infectious
bites or from a single multiply infectious bite, whereas with
cross-reactivity it could derive only from the latter. Accord-
ingly, here we expand our modeling framework to investigate
recombination among P. falciparum genotypes and how its
characteristics might be influenced by specific structures of
cross-reactivity.
MATERIALS AND METHODS
Our discrete-event models of P. falciparum transmission
use a single timeline variable to track each parasite life cycle
within and between individuals (Fig. 1). We have previously
described the assumptions, implementation, and behaviors of
the model in detail and compared them to those of classic
malaria-transmission models (McKenzie et al. 1998, 1999).
Within the model, a given number of humans and mos-
quitoes are drawn at random each day, with replacement, for
interaction through the taking of bloodmeals. Following Mac-
donald (1957) and our previous work, we fix the number of
such bites per day at one-half the number of vectors and
assume that humans are the sole source of bloodmeals. We
generally assume a 10:1 ratio of mosquitoes to humans, again
following Macdonald (but see McKenzie et al. 1998). The
mosquito-dynamics component of the model assumes a con-
stant daily probability of death (parameter range 0.046–
0.139, half-life five to 15 days, in accord with field data),
and in our previous work each dead mosquito was replaced
with one newly emerged adult. Here each dead mosquito is
replaced by a number of newly emerged adults that is a Pois-
son random variable with parameter K/N, where N is the
current mosquito population size and the value of K a pa-
rameter in the model (set here at 5000). Because the number
of mosquito deaths in a day is generally large (.10), we can
approximate the Poisson by a normal random variable with
mean and variance K/N, rounding the result to an integer
(Haight 1967). The effect of density dependence swamps the
stochastic fluctuations, so that even in very small mosquito
populations (;25) the probability of vector extinction is near
zero.
The model defines immunity in terms of an individual hu-
man’s susceptibility to reinfection with a given parasite en-
tity, determined by a daily decay of protection after clearance
of infection with that entity. The absence of definitive em-
pirical data makes it difficult to determine a relevant param-
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FIG. 2. The six cross-immunity matrices, m0–m5, with the four distinct genotypes in each given as a two-locus, two-allele system Ab,
aB, AB, ab. The two parental genotypes are the initial, equilbrium Ab and the introduced aB; the two recombinants are ab and AB. Note
that matrices m0, m1, m4, and m5 are symmetric with respect to cross-immunity between genotypes, whereas matrices m2 and m3 are
asymmetric.
eter range under this operational (or any other) definition of
human immunity in malaria. Our previous work focussed on
100 days as a standard half-life of immunity and systemat-
ically explored the effects of values ranging from 50 to 150
days. Here we set 2000 days as a standard half-life. With
this one change, we repeated all previous runs and system-
atically explored the effects of half-lives ranging from 1000
to 3000 days. Each prevalence-response surface proved to be
lower than those with the shorter immunity half-lives, but
remained well within the bounds of field data from perennial-
transmission regions and fully in accord with the qualitative
conclusions of our previous work.
The model defines cross-reactivity between parasite enti-
ties as complete and reciprocal, that is, entities that are cross-
reactive share every aspect of a host’s immune-response dy-
namics except, in general, the phenotype-specific value of
the immune-decay parameter. Thus, the probability that a
human individual becomes infected when challenged by in-
oculation depends not only on those parasite entities actually
in the inoculum or those with which the individual was most
recently infected, but on all those with which each is con-
nected through cross-reactivity. The probability of
(re)infection with each entity is calculated in accord with the
lowest probability of infection; that is, for each genotype in
an inoculum, a probability of infection is calculated for all
genotypes within its cross-reactivity group in the challenged
individual’s infection history. Then for each genotype in the
inoculum, independently, the lowest of these probabilities is
taken as the probability of infection for that genotype in a
Bernoulli trial. We represent each possible combination of
the presence and absence of cross-reactivity among the four
genotypes as a pattern of ones and zeros in a 4 3 4 matrix,
and refer to each distinct combination by a matrix number.
The dynamic repertoire of the system could be increased by
incorporating fractional or asymmetric values, but there is as
yet no clear empirical basis for doing so with respect to
malaria. Here we set the values of the immune-decay param-
eter for the four genotypes equal, then consider six cross-
reactivity matrices, m0–m5 (Fig. 2); we refer to the four
distinct genotypes in each by the notation Ab, aB, AB, ab.
Note that matrices m0, m1, m4, and m5 are symmetric with
respect to cross-reactivity between genotypes, whereas ma-
trices m2 and m3 are asymmetric.
We have modeled the life history of the parasite in the
vector in more detail than in previous work. This resolves a
discrepancy between our earlier models and field data—sub-
stituting a probability for the certainty that a mosquito feed-
ing on a gametocyte carrier becomes infected—and allows
us to represent the dynamics of recombination between P.
falciparum genotypes, initially within a two-locus, two-al-
lele-per-locus system. An additional parameter in the ex-
panded model represents a recombination rate between the
loci, 0 # r # 1. For each mosquito bloodmeal taken, the
probability distribution of oocyst genotypes that might result
from the bloodmeal is calculated using the given value of r
and the distribution of gametocyte genotypes in the blood-
meal. The number of oocysts resulting from the bloodmeal
is a Poisson random variable with parameter 0.8 (in accord
with data on naturally infected Anopheles gambiae; Pringle
1966; Haji et al. 1996); a sample of that size is drawn from
the probability distribution of genotypes calculated above.
With this representation, on average roughly 55% of mos-
quito feeds on gametocyte carriers produce oocysts, again in
line with field data (Carter and Graves 1988; Toure et al.
1998). Note that each genotype is considered as present in
the given gametocyte pool or not; relative densities of the
gametocyte genotypes do not enter into the calculation of the
ookinete frequencies. When a mosquito is superinfected, any
resulting oocysts are added to those already present from
prior infections; thus, all else being equal, older mosquitoes
will have higher oocyst densities.
With this additional change, with r 5 0, we repeated all
previous runs, and found the prevalence surfaces lower but
still clearly in accord with field data. Two qualitative changes
from our previous conclusions emerged, each of which fol-
lows logically from more realistic mosquito-infection prob-
abilities: (1) with fully independent phenotypes, the relative
influence of vector mortality on overall prevalence is, on
average, clearly greater than that of the duration of host in-
fectivity; and (2) with fully cross-reactive phenotypes, the
relative influence of the duration of host immunity is, on
average, clearly equal to that of the duration of human in-
fectivity. We also found that with parameter sets that combine
the maximum vector mortality, the minimum duration of in-
fectivity, and the maximum duration of immunity (0.139, 10,
3000), spontaneous extinctions of the parasite occurred with-
in three years in up to 20–25% of runs.
We set the host population size at 500, fix the intervals
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required to progress from an infected to an infectious state
at 10 and 20 days for the vector and host, respectively, and
allow the duration of host infectivity to range from 10 to 30
days (McKenzie et al. 1998, 1999). We initiate each replicate
run with none of the vectors infected and with 15% of the
hosts infected with a single genotype. Within two years, this
initial genotype reaches equilibrium prevalence; we then in-
troduce a second genotype, in the form of a single infectious
human, and continue the run for three more years. Below we
refer to the initial, equilibrium, and the introduced genotypes
jointly as the ‘‘parental’’ genotypes, and to their distinct
progeny jointly as the ‘‘recombinants.’’
For each of the replicate runs, for each cross-reactivity
matrix, for each recombinant form we recorded the number
of runs in which it appeared in at least one human infection,
the day of its (first) appearance, and its average prevalence
over the final year. Each prevalence figure below encom-
passes the infected and the infectious states and represents
an average over all replicates for a given parameter set (stan-
dard deviations ,0.01). All prevalence figures are calculated
over the fifth and final year; they exclude runs in which
parasite extinction occurred during the first four years, but
include those in which extinction occurred in the final year.
We defined a run in which a recombinant became established
in the human population as one in which its average prev-
alence over the final (fifth) year was .0.0005 (equivalent to
three or four completed infections over the course of the
year). In each instance, for each recombinant we calculated
its frequency of appearance as the number of appearances
over the number of replicates, and its frequency of estab-
lishment as the number of establishments over the number
of appearances (excluding cases in which there were no ap-
pearances).
For each cross-reactivity matrix, we completed 1000 rep-
licate runs with the parameter set at the midpoint of the
parameter space defined above. To investigate the robustness
of these results, for each cross-reactivity matrix we also com-
pleted 100 replicate runs with each of 81 parameter sets that
define the parameter space (recombination rate 5 0.0005,
0.001, or 0.005; vector half-life 5 5, 10, or 15 days; duration
of host infectivity 5 10, 20, or 30 days; half-life of human
immunity 5 1000, 2000, or 3000 days). These parameter
ranges are consistent with the available empirical data
(McKenzie et al. 1998), and, in conjunction, lead to a wide
range in overall malaria prevalence (0.08–0.97) that is con-
sistent with empirical data. In comparing frequencies of ap-
pearance, and frequencies of establishment, both within and
between cross-reactivity matrices, for each parameter set we
applied Fisher’s exact test (Sokal and Rohlf 1981) to the
contingency tables for the appropriate pairs of recombinants.
To correct for multiple comparisons and a finite number of
replicates (Berry and Lindgren 1990), for each such pair,
across all 81 parameter sets, we compared the number of
tables with calculated P-values ,0.05 to the number expected
under a binomial distribution with the (Bernoulli) P fixed
equal to the corresponding P-value calculated by Fisher’s
test. For each such pair, we ranked the average day of ap-
pearance and average prevalence for each parameter set, then
compared the overall totals.
Our efforts to assemble and organize the known facts about
P. falciparum meiotic recombination included close exami-
nation of the literature and consultation with a dozen prom-
inent malariologists. This process revealed an unexpected gap
in current biological knowledge, in the form of irreconcilable
assumptions about whether at most one, two, or four geno-
types might be represented within a single P. falciparum oo-
cyst. Furthermore, the adherents of each set of assumptions
seemed unaware that any such disagreement exists.
All parties agree that the only diploid stage in the Plas-
modium life cycle is the zygote, and that the products of
meiosis are haploid. However, it appears that the electron-
microscopy studies undertaken in the 1980s by Sinden and
his colleagues ended and were considered supplanted by stud-
ies based on molecular techniques, shortly before a crucial
question was resolved: ‘‘Although this study identifies the
meiotic division, it is not yet established whether the fertil-
ized zygote replicates from a diploid (2N) condition to 4N
prior to meiosis. . . . We have obtained numerous pictures
. . . indicating that there are at least three and probably four
kinetochores on each synaptonemal complex. . . . We believe
that there are four chromatids in each synaptonemal complex,
i.e., the zygote has indeed replicated to a 4N condition prior
to meiosis. . . . This interpretation contrasts with previous
data on the related sporozoan parasite Eimeria, in which the
fertilized zygote moves directly from a 2N organization back
to a haploid genome at the first meiotic division’’ (Sinden
and Hartley 1985, p. 744). Most subsequent reviews of Plas-
modium genetics seem to take two-step meiosis as established
fact (e.g., see figure 1 in Walliker et al. 1998).
However, it is not clear that more recent results—even
from single oocysts, with genes known to be single copy
(e.g., MSP-1, Ranford-Cartwright et al. 1991)—exclude the
possibility that Plasmodium conforms to the single-step pat-
tern of other Sporozoa, and there may be alternative expla-
nations for the kinetochore counts cited above. Viewed in
this light, in detail, some data and language in recent studies
become unexpectedly ambiguous (e.g., with respect to ‘‘lev-
els of heterozygosity in oocysts,’’ Anderson et al. 2000b).
Furthermore, several of our advisors maintain that the zygote-
ookinete-oocyst transformation leads (perhaps with rare ex-
ceptions) to exactly one genotype per oocyst. Our current,
albeit tentative, view is that Sinden’s hypothesis is the most
likely and the one-genotype-per-oocyst hypothesis the least
likely, with the phylogenetic-conformance hypothesis inter-
mediate between these; accordingly, the model presented be-
low is of a process in accord with Sinden and Hartley’s (1985)
hypothesis. However, we carried out precisely parallel studies
with models that incorporate the 2 alternative hypotheses.
RESULTS
Table 1 presents results from 1000 replicate runs with each
of the six matrices, from the parameter set at the midpoint
of the parameter space. These results are consistent over the
full range of 81 parameter sets.
First we present results for the four symmetric matrices,
m0, m1, m4, and m5 (Fig. 2). With respect to frequencies of
recombinant-form (AB, ab) appearance, the matrices rank as
follows: m0 . m4 . m1 . m5. With respect to frequencies
of recombinant-form establishment, the matrices rank as fol-
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TABLE 1. Results on recombinants from 1000 replicate runs with each of the six matrices, with the parameter set at the midpoint of the
parameter space (recombination rate 0.001; vector half-life 10 days; duration of host infectivity 20 days; half-life of human immunity 2000
days). Numbers of appearances and establishments refer to the number of replicates in which a recombinant appeared in a human and the
number in which a recombinant persisted in the human population, respectively (see text). These results are consistent over the full range of
81 parameter sets.
Matrix
Number of
appearances
Number of
establishments
Average day of
first appearance
Average prevalence in final year
Overall Initial (Ab) Introduced (aB) Mixed (Ab, aB)
Recombinant
(ab, AB)
m0
m4
m1
m5
m2.ab
m2.AB
m3.ab
m3.AB
1000
362
138
7
1000
313
154
20
1000
61
133
3
1000
50
151
12
883
1259
1394
1496
815
1259
1445
1517
0.84
0.61
0.44
0.40
0.75
—
0.43
—
0.37
0.38
0.28
0.28
0.37
—
0.27
—
0.37
0.38
0.13
0.13
0.37
—
0.13
—
0.14
0.14
0.00
0.00
0.14
—
0.00
—
0.37
0.00
0.04
0.00
0.37
0.00
0.04
0.00
FIG. 3. The frequency distributions of the day of the first recombinant appearance in a human, over 1000 runs for matrices m0 (bars)
and m1 (line), with the parameter set at the midpoint of the parameter space. In each run, after two years the initial genotype Ab had
reached equilibrium, the genotype AB was introduced, and the run continues for three more years (see text). Here day 0 represents day
720 overall, that is, the day on which type aB was introduced. The mean first recombinant appearance for m0 was on day 97 and for
m1 on day 674.
lows: m0 5 m1 . m4 5 m5. In all four symmetric matrices,
the frequencies of appearance and of establishment of AB
are indistinguishable from those of ab, as would be expected.
In general, matrices that lead to higher frequencies of ap-
pearance and higher frequencies of establishment are asso-
ciated with earlier dates of first recombinant appearance. For
instance Figure 3 illustrates the contrast between m0 and m1,
again using the parameter set at the midpoint of the parameter
space. The peak in the frequency in m0, at three months after
the introduction of the new genotype aB, occurs because no
prior immunity to aB exists at its introduction, so the prev-
alence of aB and of mixed infections with aB and Ab rises
quickly. Accordingly, the prevalence of the recombinants ab
and AB rises soon thereafter. These peaks in prevalence pro-
duce a peak in immunity, so the frequency of aB and of mixed
infections with aB and Ab drops quickly, as does the pro-
duction of recombinants. The system then rebounds and
shows an oscillating but relatively steady fall-off in the first
appearances of recombinants.
With respect to the average final-year prevalence of in-
fection overall, that is, infection with any genotype or com-
bination of genotypes, the matrices rank as they do for fre-
quencies of appearance: m0 . m4 . m1 . m5. With respect
to the final-year prevalence of the initial (Ab) and introduced
(aB) genotypes: m0 5 m4 . m1 5 m5. With matrices m0
and m4, the prevalence of Ab is indistinguishable from that
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FIG. 4. The daily prevalence dynamics in a single run with matrix m3. All parameter values are as in the parameter set at the midpoint
of parameter space, and day 0 represents day 720 overall, that is, the day on which type aB was introduced. The solid line represents
the initial, established genotype Ab, the dotted line the introduced aB. Recombinant form AB did not appear in a human in this run; ab
(dashed line) appeared in a human in 43% of runs with this parameter set, AB in only 4%.
of aB; with m1 and m5, the prevalence of Ab is greater than
that of aB. With matrices m0 and m4, the observed prevalence
of mixed-genotype infections with Ab and aB is equal to that
expected by the product of the genotype prevalences; with
matrices m1 and m5, the observed prevalence is much less
than that expected. With respect to the prevalence of the
recombinants (AB and ab), the matrices rank as follows: m0
. m1 . m4 5 m5. In all four symmetric matrices, the prev-
alence of ab is indistinguishable from that of AB, as would
be expected. The prevalence of mixed-parental-genotype in-
fections drops dramatically with parental-parental cross-im-
munity; the prevalence of recombinants drops dramatically
with parental-recombinant cross-immunity.
With respect to frequencies of recombinant-form appear-
ance and establishment, dates of first recombinant appear-
ance, and average final-year prevalences, the behavior of each
of the recombinants in the asymmetric matrices m2 and m3
is indistinguishable from that of the recombinants in one of
the four symmetric matrices, as follows: m2.ab 5 m0, m2.AB
5 m4, m3.ab 5 m1, and m3.AB 5 m5. With respect to the
final-year prevalence of the initial and introduced genotypes
Ab and aB respectively, m2 is indistinguishable from m0 and
m4, and is greater that m3, which is indistinguishable from
m1 and m5. With m2, the prevalence of Ab is indistinguish-
able from that of aB; with m3, the prevalence of Ab is greater
than that of aB. With matrix m2, the observed prevalence of
mixed-genotype infections with Ab and aB is equal to that
expected by the product of the genotype prevalences; with
matrix m3, the observed prevalence is much less than that
expected. In accord with equivalencies noted above, in both
asymmetric matrices the frequency of appearance, frequency
of establishment, and final-year prevalence of ab are greater
than those of AB, and the overall malaria prevalence is in-
termediate between the corresponding symmetric matrices.
Figure 4 illustrates the dynamics in a single run with matrix
m3, in which all genotypes but the recombinant ab are cross-
reactive. Typically, the recombinant form AB failed to appear
in a host during this run. Following its introduction, the prev-
alence of genotype aB increases slowly, because the host
population has a high level of immunity to genotype Ab. The
rising prevalence of aB suppresses the prevalence of Ab. The
immunologically independent recombinant ab appears for the
first time 28 months after the introduction of aB and displays
dynamics typical of a genotype in a naive host population.
Its sudden rise in prevalence reflects the nearly simultaneous
infection of a large fraction of the host population, which
synchronizes host immunity and produces a rapid decline in
prevalence to a level well below its eventual equilibrium.
In sum, cross-reactivity between the parental types pro-
duces lower frequencies of appearance. Cross-reactivity be-
tween the parental and recombinant forms also produces low-
er frequencies of appearance, although with less marked ef-
fect, and, unlike cross-reactivity between the parental types,
it produces dramatically lower frequencies of establishment.
With cross-reactivity both between the parental and recom-
binant forms and between the parental types, frequencies of
establishment are greater than with only parental-recombi-
nant cross-reactivity. Parental-recombinant cross-reactivity
influences overall prevalence solely through its influence on
the prevalence of recombinants. Parental-parental cross-re-
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TABLE 2. Results on recombinants from 1000 replicate runs with each
of the six matrices (parameter set as in Table 1), with models that
incorporate the two alternative hypotheses about the maximum number
of parasite genotypes in a single oocyst. The appearance and estab-
lishment figures are given as ratios in relation to the corresponding
figures in Table 1. We do not show the average day of first appearance,
which for the one-genotype model ranged from three months earlier
to three months later, and for the two-genotype model from four months
earlier to one month later than the four-genotype model. All average
final-year prevalence figures were within 0.01 of those in Table 1.
Results for each model are consistent across all 81 parameter sets.
Matrix
One genotype/oocyst
Number of
appearances
Number of
establishments
Two genotypes/oocyst
Number of
appearances
Number of
establishments
m0
m4
m1
m5
m2.ab
m2.AB
m3.ab
m3.AB
1.00
0.46
0.72
0.86
1.00
0.51
0.60
0.35
1.00
0.39
0.80
1.00
1.00
0.48
0.61
0.33
1.00
0.92
1.07
1.71
1.00
1.03
1.05
0.80
1.00
0.89
1.10
1.67
1.00
110
1.04
0.67
activity influences all components of overall prevalence, but
the frequency of establishment and prevalence of recombi-
nants are higher with parental-parental than with parental-
recombinant cross-reactivity.
Table 2 presents results from two alternative models, in-
corporating the hypotheses that there is at most one genotype
or at most two genotypes in a single P. falciparum oocyst.
Although differences from the four-genotype-per-oocyst
model are quantitative rather than qualitative, they are suf-
ficiently striking to merit attention.
DISCUSSION
Our results argue that rates of parasite evolution are influ-
enced by cross-reactivity between parental genotypes and
between recombinant and parental genotypes; each form of
cross-reactivity exerts strong but somewhat different effects.
Outcrossed recombinants arise in mosquitoes primarily from
mixed parental-genotype infections in humans, the frequen-
cies of which are influenced most strongly by cross-reactivity
between the parental genotypes. Frequencies of recombinant
appearance also decline with the presence of parental-recom-
binant cross-reactivity because recombinants generated in the
mosquito are likely to encounter an effective immune re-
sponse when inoculated into a host. Once a novel recombi-
nant emerges in a human population, its probability of per-
sistence is influenced most strongly by cross-reactivity with
its parental forms. In this context, although cross-reactivity
between the parental genotypes reduces the prevalence of
each, and thus the frequency of outcrossing, it also reduces
the probability that a novel recombinant will be inoculated
into an effectively immune host.
Novel recombinants are most likely to derive from im-
munologically novel invaders, not because the invading pa-
rental genotype produces a novel protein per se, but because
it bypasses the bottlenecks in transmission that govern the
dynamics of parasite recombination. It is important to note
that the structure of cross-immunity between the model ge-
notypes here is in no way necessarily tied to or dependent
on the loci or alleles involved in recombination. At least two
of the cross-reactivity matrices could be considered to rep-
resent relationships among alleles of antigen-producing loci,
however: allele- and locus-specific cross-reactivity involving
both alleles at both loci (m4) or allele-specific cross-im-
munity involving one allele at each locus (m2). Matrix m3
might represent a relationship in which the antigenic products
of one allele at each locus are cross-reactive. Nonetheless,
our results suggest that the effects of cross-reactivity on P.
falciparum population genetics extend beyond specific anti-
gen-producing loci; for example, a drug-resistant recombi-
nant might be less likely to emerge were its parental geno-
types cross-reactive.
Values for some parameters in our model are not known
as yet, and the values of others are known to vary widely in
nature. Accordingly, we examined ranges of values that cor-
respond to the available empirical data. Our comparisons of
cross-reactivity matrices produced results robust over all of
the parameter sets and indicated that in this context cross-
reactivity structures influence the emergence, persistence,
and prevalence of novel genotypes more than do parameter
sets. However, it is also clear that important changes in sys-
tem dynamics can proceed from specific changes at the level
of the parameter values themselves. For instance, in accord
with Tanaka and Feldman (1999), we note that changes in
recombination rate affect the success of an invading genotype
primarily by affecting the magnitude of the advantage or
disadvantage conferred by its position in a particular cross-
reactivity (interference) structure. In broad terms, our results
support the conclusions of several other recent modelers, in
particular that immune-mediated relationships among geno-
types may shape and be shaped by P. falciparum evolution.
Thus, it seems possible that intervention could disrupt these
ecological relationships so as to release vaccine-evading var-
iants from competitive suppression (Gupta et al. 1997) or
facilitate the spread of drug resistant mutants (Hastings and
Mackinnon 1998).
Our model has a number of shortcomings, some of which
might be addressed by incorporating more detailed models
of within-host parasite dynamics (McKenzie and Bossert
1997b, 1998). The model considers only binary densities in
the transmission of genotypes, either as gametocytes or spo-
rozoites, and, in more general terms, although our operational
definition of immune functions is adequate for the present
purpose, we look forward to much more detailed, mechanistic
representations of immune responses.
More detailed immune-response representations will be es-
sential to models that connect clinical disease to malaria in-
fection. For instance, in sub-Saharan Africa, malaria mor-
tality and morbidity are generally low among those adults
and older children exposed to at least five infections per year;
high mortality is limited to infants and young children. Ma-
laria prevalence is typically high in both groups, and the
clinical difference is said to arise from cumulative exposure
to the antigenic repertoire of the parasite, leading to greater
cross-reactive immunity with age. However, an alternative
hypothesis attributes the difference to intrinsic age-related
immune factors independent of cumulative exposure, shifting
the focus of risk much more toward the host than the parasite
(Baird 1995). It is critical that this question be resolved, in
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part because most vaccines under development to reduce mor-
tality in Africa expect to mimic the naturally acquired im-
munity of adults.
We also expect that the unanticipated questions about mei-
osis in P. falciparum—concerning the mechanics of parasite
genotype packaging in oocysts, and thus the biological units
subject to survivorship and selection (Vaughan et al. 1992)—
will be resolved. In the present context, differences between
the three hypotheses have quantitative rather than qualitative
consequences; although none affect our conclusions here,
their implications for other avenues of malaria research are
significant.
The slow and imperfect acquisition of immunity in human
malaria is usually attributed to the antigenic diversity of the
parasite, and the antigenic diversity of the parasite is usually
attributed to its obligate sexual recombination in Anopheles.
Our current knowledge of P. falciparum genetics is heavily
biased toward a few drug-resistance or strongly immunogenic
vaccine-candidate genes, however, and even in these we
know little about linkage and nothing about mutation rates.
Furthermore, it may be that evolutionary trajectories differ
among antigen-producing loci (Escalante et al. 1998) and
even among allelic families at a single antigen-producing
locus (Felger et al. 1997). Longitudinal studies of infected
individuals have begun to reveal complex day-to-day dynam-
ics involving variously defined P. falciparum allelic types
(Daubersies et al. 1996; Farnert et al. 1997), but we do not
understand how parasite dynamics within individuals relate
to those in human and vector populations (Arnot 1998; Druil-
he et al. 1998).
Malaria intervention programs should be rationally de-
signed, executed, and evaluated, and so should encompass a
detailed understanding of the population-genetic and cross-
reactivity structures of P. falciparum populations, how these
structures interact in the evolution of the parasite, and how
such interactions may vary with place, time, and the inter-
vention programs themselves. Biased frequencies of parasite
genotypes transmitted to mosquitoes under drug pressure will
be crucial to the spread of resistance, and, under vaccine
pressure, to the spread of evasive antigenic variants. It would
be extremely premature to expect a deep understanding of
any system of this complexity on the basis of the meager
current data. Furthermore, a deep understanding will require
not only a great deal more data, but an array of formal ex-
planatory models incorporating as many of relevant factors
as possible, in a realistic but comprehensible manner. Our
discrete-event implementation cannot replace more abstract
approaches or preempt more precise site-specific simulations,
but can serve as a bridge between them, thus allowing in-
tegration and comparison of data from different places, times,
and disciplines.
ACKNOWLEDGMENTS
We gratefully acknowledge the contributions of C. Gaab,
K. Hoffman, R. L. Merriam, J. Moore, E. Pickens, M. Riley,
J. Simek, B. C. Sorkin, N. Vecchione, and two anonymous
reviewers. FEM is supported by a NIH National Research
Service Award, MUF by FAPESP and the UNDP/World-
Bank/WHO Special Program for Research and Training in
Tropical Diseases.
LITERATURE CITED
Anderson, T. J. C., B. Haubold, J. T. Williams, J. G. Estrada-Franco,
L. Richardson, R. Mollinedo, M. Bockarie, J. Mokili, S. Mhar-
akurwa, N. French, J. Whitworth, I. D. Velez, A. Brockman, F.
Nosten, M. U. Ferreira, and K. P. Day. 2000a. Microsatellites
reveal a spectrum of population structures in the malaria parasite
Plasmodium falciparum. Mol. Biol. Evol. 17:1467–1482.
Anderson, T. J. C., R. E. L. Paul, C. A. Donnelly, and K. P. Day
2000b. Do malaria parasites mate non-randomly in the mosquito
midgut? Genet. Res. 75:285–296.
Arnot, D. 1998. Clone multiplicity of Plasmodium falciparum in-
fections in individuals exposed to variable levels of disease
transmission. Trans. R. Soc. Trop. Med. Hyg. 92:580–585.
Ayala, F. J., A. A. Escalante, A. A. Lal, and S. M. Rich. 1998.
Evolutionary relationships of human malaria parasites. Pp. 285–
300 in I. W. Sherman, ed. Malaria. ASM Press, Washington,
D.C.
Baird, J. K. 1995. Host age as a determinant of naturally acquired
immunity to Plasmodium falciparum. Parasitol. Today 11:
105–111.
———. 2000. Resurgent malaria at the milennium. Drugs 59:
719–743.
Berry, D. A., and B. W. Lindgren. 1990. Statistics. Brooks-Cole,
Pacific Grove, CA.
Buckling, A., L. C. Ranford-Cartwright, A. Miles, and A. F. Read.
1999. Chloroquine increases Plasmodium falciparum gameto-
cytogenesis in vitro. Parasitology 118:339–346.
Carter, R., and P. M. Graves. 1988. Gametocytes. Pp. 253–306 in
W. H. Wernsdorfer and I. McGregor, eds. Malaria. Churchill
Livingstone, Edinburgh.
Daubersies, P., S. Sallenave-Sales, S. Magne, J.-F. Trape, H. Con-
tamin, T. Fandeur, C. Rogier, O. Mercereau-Puijalon, and P.
Druilhe. 1996. Rapid turnover of Plasmodium falciparum pop-
ulations in asymptomatic individuals living in a high transmis-
sion area. Am. J. Trop. Med. Hyg. 54:18–26.
Druilhe, P., P. Daubersies, J. Patarapotikul, C. Gentil, L. Chene, T.
Chongsuphajaisiddhi, S. Mellouk, and G. Langsley. 1998. A
primary malarial infection is composed of a very wide range of
genetically diverse but related parasites. J. Clin. Invest. 101:
2008–2016.
Escalante, A. A., A. A. Lal, and F. J. Ayala. 1998. Genetic poly-
morphism and natural selection in the malaria parasite Plas-
modium falciparum. Genetics 149:189–202.
Farnert, A., G. Snounou, I. Rooth, and A. Bjorkman. 1997. Daily
dynamics of Plasmodium falciparum subpopulations in asymp-
tomatic children in a holoendemic area. Am. J. Trop. Med. Hyg.
56:538–547.
Felger, I., V. M. Marshall, J. C. Reeder, J. A. Hunt, C. S. Mgone,
and H. P. Beck. 1997. Sequence diversity and molecular diver-
sity of the merozoite surface antigen 2 of Plasmodium falcipa-
rum. J. Mol. Evol. 45:154–160.
Ferreira, M. U., Q. Liu, M. Kimura, B. T. Ndawi, K. Tanabe, and
F. Kawamoto. 1998. Allelic diversity in the merozoite surface
protein-1 and epidemiology of multiple-clone Plasmodium fal-
ciparum infections in Northern Tanzania. J. Parasitol. 84:
1286–1289.
Gilbert, S. C., M. Plebanski, S. Gupta, J. Morris, M. Cox, M. Aidoo,
D. Kwiatkowski, B. M. Greenwood, H. C. Whittle, and A. V.
S. Hill. 1998. Association of malaria parasite population struc-
ture, HLA, and immunological antagonism. Science 279:
1173–1177.
Gupta, S., N. M. Ferguson, and R. M. Anderson. 1997. Vaccination
and the population structure of antigenically diverse pathogens
that exchange genetic material. Proc. R. Soc. Lond. B 264:
1435–1443.
Haight, F. A. 1967. Handbook of the Poisson distribution. John
Wiley, New York.
Haji, H., T. Smith, J. D. Charlwood, and J. H. Meuwissen. 1996.
1307PLASMODIUM FALCIPARUM RECOMBINATION
Absence of relationships between selected human factors and
natural infectivity of Plasmodium falciparum to mosquitoes in
an area of high transmission. Parasitology 113:425–431.
Hastings, I. M., and M. J. Mackinnon 1998. The emergence of drug-
resistant malaria. Parasitology 117:411–417.
Healer, J., D. McGuinness, R. Carter, and E. Riley. 1999. Trans-
mission-blocking immunity to Plasmodium falciparum in ma-
laria-immune individuals is associated with antibodies to the
gamete surface protein Pfs230. Parasitology 119:425–433.
Macdonald, G. 1957. The epidemiology and control of malaria.
Oxford Univ. Press, London.
McKenzie, F. E., and W. H. Bossert. 1997a. Mixed-species Plas-
modium infections of Anopheles (Diptera: Culicidae). J. Med.
Entomol. 34:417–425.
———. 1997b. The dynamics of Plasmodium falciparum blood-
stage infection. J. Theor. Biol. 188:127–140.
———. 1998. The optimal production of gametocytes by Plas-
modium falciparum. J. Theor. Biol. 193:419–428.
———. 1999. Multispecies Plasmodium infections of humans. J.
Parasitol. 85:12–18.
McKenzie, F. E., R. C. Wong, and W. H. Bossert. 1998. Discrete-
event simulation models of Plasmodium falciparum malaria.
Simulation 71:250–261.
———. 1999. Discrete-event simulation models of mixed-pheno-
type Plasmodium falciparum malaria. Simulation 73:213–217.
Paul, R. E. L., A. Brockman, R. N. Price, C. Luxemburger, N. J.
White, S. Looareesuwan, F. Nosten, and K. P. Day. 1999. Ge-
netic analysis of Plasmodium falciparum infections on the north-
western border of Thailand. Trans. R. Soc. Trop. Med. Hyg. 93:
587–593.
Pringle, G. 1966. A quantitative study of naturally-acquired malaria
infections in Anopheles gambiae and Anopheles funestus in a
highly malarious area of East Africa. Trans. R. Soc. Trop. Med.
Hyg. 60:626–632.
Ranford-Cartwright, L. C., P. Balfe, R. Carter, and D. Walliker.
1991. Genetic hybrids of Plasmodium falciparum identified by
amplification of genomic DNA from single oocysts. Mol. Bio-
chem. Parasitol 49:239–244.
Sinden, R. E., and R. H. Hartley. 1985. Identification of the meiotic
division of malarial parasites. J. Protozool. 32:742–744.
Snounou, G., X. Zhu, N. Siripoon, W. Jarra, S. Thaithong, K. N.
Brown, and S. Viriyakosol. 1999. Biased distribution of msp1
and msp2 allelic variants in Plasmodium falciparum populations
in Thailand. Trans. R. Soc. Trop. Med. Hyg. 93:369–374.
Sokal, R. R., and F. J. Rohlf. 1981. Biometry. W. H. Freeman, New
York.
Tanaka, M. M., and M. W. Feldman. 1999. Theoretical consider-
ations of cross-immunity, recombination and the evolution of
new parasitic strains. J. Theor. Biol. 198:145–163.
Toure, Y. T., O. Doumbo, A. Toure, M. Bagayoko, M. Diallo, A.
Dolo, K. D. Vernick, D. B. Keister, O. Muratova, and D. C.
Kaslow. 1998. Gametocyte infectivity by direct mosquito feeds
in an area of seasonal malaria transmission: implications for
Bancoumana, Mali, as a transmission-blocking vaccine site. Am.
J. Trop. Med. Hyg. 59:481–486.
Vaughan, J. A., B. H. Noden, and J. C. Beier. 1992. Population
dynamics of Plasmodium falciparum sporogony in laboratory-
infected Anopheles gambiae. J. Parasitol. 78:716–724.
Walliker, D., H. Babiker, and L. Ranford-Cartwright. 1998. The
genetic structure of malaria parasite populations. Pp. 235–252
in I. W. Sherman, ed. Malaria. ASM Press, Washington, D.C.
Corresponding Editor: M. Riley
